Categories Earnings, Health Care

Avid Bioservices stock jumps after Q3 loss narrows on higher revenues

Avid Bioservices (CDMO) reported a narrower net loss for the third quarter of 2019, aided by a sharp increase in revenues and lower expenses. The results also topped analysts’ expectations. The company’s stock jumped about 4% during the extended trading session Monday following the announcement.

The Tustin, California-based biotech contract manufacturer reported a net loss attributable to common stockholders of $2.6 million or $0.05 per share for the third quarter, compared to a loss of $12.4 million or $0.28 per share a year earlier. Analysts had forecast a wider loss for the most recent quarter. Boosting the turnaround, selling, general & administrative expenses dropped 33% to $3.2 million.

Contract manufacturing revenues more than doubled to $13.8 million – far exceeding expectations – reflecting higher demand from a more diversified client base. The improved topline performance translated into positive gross margins, which recovered from a negative 61% to a positive 15% helped by a favorable product mix and higher volumes.

The improved topline performance translated into an improvement in gross margins helped by a favorable product mix and higher volumes.

During the three-month period, the management expanded several ongoing projects. The company said it is firmly on-track towards achieving profitability in the near term. The management currently expects to end the fiscal year within the lower half of its revenue guidance of $51-$55 million.

“The third quarter was busy and productive as reflected by our strong financial results. Our process development group is increasingly busy, now contributing over 20% of revenues.  With respect to new projects, we continue to see growth in the number of RFPs received,” said CEO Roger Lias.

Also see: Avid Bioservices Q3 2019 Earnings Conference Call Transcript

Recently, Abbott Laboratories (ABT) reported a net profit for the fourth quarter compared to a loss last year, helped by lower tax expense. The biotech firm swung to a profit of $0.37 per share even as worldwide sales moved up 2.3% aided by a strong performance by the Medical Devices and Diagnostics businesses.

Shares of Avid Bioservices closed Monday’s regular session sharply higher and gained further in the after-hours session, reversing the trend seen since the beginning of the year. The stock rose about 56% in the past twelve months but often underperformed the sector.

Earnings Transcript: Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Lamb Weston (LW) Q4 2024 Earnings: Key financials and quarterly highlights

Lamb Weston Holdings, Inc. (NYSE: LW) reported its fourth quarter 2024 earnings results today. Net sales declined 5% year-over-year to $1.61 billion. Net income decreased 74% to $130 million, or

Visa (V) reports double-digit growth in Q3 revenue, profit

Credit card giant Visa (NYSE: V) has reported strong revenue and earnings growth for the third quarter of 2024, reflecting a sharp increase in payment volume and cross-border volume. Adjusted

T Earnings: Key quarterly highlights from AT&T’s Q2 2024 financial results

AT&T (NYSE:T) reported its second quarter 2024 earnings results today. Revenues dipped slightly to $29.8 billion from $29.9 billion in the year-ago quarter. Net income attributable to common stock was

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top